Reimbursement models to practicing physicians continue to evolve. Many oncologists have been skeptical about MACRA (which was enacted into law) and how it might affect their ability to deliver cost-effective care, without compromising patients’ access to life-saving therapies. in this OBR interview, which was conducted during the 2018 annual American Society of Hematology (ASH) meeting,
During the 2018 annual American Society of Hematology (ASH) meeting and when I was still a VP and Chief Medical Officer at Cardinal Health Specialty Solutions, I gave this interview to OBR on the potential risks faced by oncologists if they enter into a two-sided payment agreement with CMS. Reimbursement models continue to fascinate me
What leads to physicians’ burnout? what are the contributing factors? we delved into this through market research surveys that highlighted the underlying issues. I summarize these in this OBR interview that took place during the 2018 annual American Society of Hematology (ASH) meeting.
During the 2018 annual American Society of Hematology (ASH) meeting, I was hosted by CLL Society and Dr. Brian Kauffman to discuss recent research I had presented at that meeting on the economic impact of using venetoclax versus chemotherapy or chemoimmunotherapy for patients with CLL. This was a poster presentation that generated a lot of
This is a republication of an article I originally wrote for the HealthCareBlog. Life is busy, yet we somehow find time to stay engaged on social media, remain engrossed in the 24/7 news cycle, and continue our futile efforts to resist clickbait. While social media can allow us to mindlessly scroll through feeds, it also provides
This opinion article was originally published at STAT news. As precision medicine opens up promising new advances in cancer care, I often think back to my early days as an oncologist, the patients I treated, and the limited treatment options I had for them. I especially remember Pam (not her real name). She was in her early
As patents for biologics emerge on the marketplace, what will be their role within the cancer community? Will biosimilars provide alternatives for cancer treatment? In addition to alternatives, what information and education is needed for stakeholders to make informed choices about the cancer treatments? During the 2018 annual American Society of Clinical Oncology (ASCO) meeting,
I was honored to be invited to the 2018 Summit on National and Global Cancer Health Disparities which was held from April 28-29 in Seattle, WA. During the meeting, I participated in a panel debate discussion on “who is responsible for rising costs of cancer care”. I was joined by fellow panelists included Don Harison,
Dr. Nabhan has been podcasting for years. His first podcast “Outspoken Oncology” started in February 2019 and won him two communication awards especially with dedicated coverage to COVID-19 when the pandemic started. That podcast retired in the summer of 2020 and Dr. Nabhan currently hosts two podcasts:
Healthcare Unfiltered: unedited and daring podcast tackling all aspects of healthcare hosting thought leaders from all over the world addressing timely and relevant debates that are important to everyone in the healthcare industry
HemOnc Pulse: Started in December 2022 and is dedicated to hematology and only hematology. Dr. Nabhan hosts thought leaders in the field of hematology discussing recent updates, new published research, debates, and asks questions that are essential to clinical care. This podcast is sponsored by Blood Cancers Today and SOHO.
